
: Absci stock rockets after collaboration with Merck could lead to more than 0 million in payments #FinanceUSA #StockMarketNEWS Shares of Absci Corp. skyrocketed 59.1% on heavy volume in premarket
@stockMarketNEWS Sun 09 Jan, 2022
Absci stock rockets after collaboration with Merck could lead to more than 0 million in payments #FinanceUSA #StockMarketNEWS
Shares of Absci Corp. skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to 0 million in upfront fees and milestone payments from Merck & Co. Inc. as part of a research collaboration agreement. Trading volume ballooned to 9.7 million shares, compared with the full-day average of about 324,800 shares, to make the stock the biggest gainer and most actively traded ahead of the open. Under the collaboration, Absci's Bionic Protein amino acid technology will be used to produce enzymes tailored to Merck's biomanufacturing platform. Merck also has the option to nominate up to three targets and enter into a drug discovery collaboration agreement. The stock, which closed at a record low of .14 on Thursday, had tumbled 42.9% over the past three months through Thursday, while the iShares Biotechnology ETF has shed 8.8% and the S&P 500 has gained 6.7%.
Munafa USA Munafa India Munafa NSE
More posts by @stockMarketNEWS

: India’s manufacturing sector grew in Dec: PMI #FinanceIndia #StockMarketNEWS #Business IANS New Delhi India’s manufacturing industry continued to grow in December 2021, albeit at a slower
@stockMarketNEWS Tue 04 Jan, 2022

: ‘COVID insurance policies to cover Omicron treatment’ #FinanceIndia #StockMarketNEWS #Business PTI New Delhi Insurance regulator Irdai on Monday said health insurance policies that cover
@stockMarketNEWS Tue 04 Jan, 2022
0 Comments
Sorted by latest first Latest Oldest Best
NSE Gainers NSE Losers BSE Gainers BSE Losers
Munafa NEWSTerms of Use Create Support ticket Your support tickets Powered by ePowerPress Stock Market News! Top Seo SMO © munafa.top2022 All Rights reserved.